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Abstract
Background: In Europe most dogs with clinical leishmaniosis are treated with leishmanicides, typically antimonials
combined with allopurinol and good clinical recovery is observed in a high number of these dogs. Through
xenodiagnosis, the capacity of a treated animal to infect the vector of the disease under treatment is assessed as a
measure of the chemotherapeutic efficacy of the drug used. The objective of the present study was to evaluate
through direct xenodiagnosis the infectivity to Phlebotomus perniciosus of dogs naturally parasitized with
Leishmania infantum after treatment, and to follow the clinical and parasite course of disease. Thirty two dogs with
clinical leishmaniosis were assigned to one of three treatment groups: meglumine antimoniate plus allopurinol
(Group A), meglumine antimoniate (Group B) or allopurinol (Group C). During the study, the dogs were examined
before treatment (Day 0) and bimonthly thereafter until Day 180 (six months post-treatment onset).
Results: The three groups were scored over time according to the effects of treatment on clinical signs and
clinical-pathological variables. Significant differences in clinical scores were observed between Group A and the
other two groups, indicating the combined treatment was the most effective. After treatment, bone marrow
cultures were positive for the parasite in 30.8% of dogs in some of the check ups (3 or 25% in Group A, 1 or 11.1%
in Group B, and 4 or 80% in Group C). Our xenodiagnosis experiments revealed that 15.4% of treated dogs were
still able to infect sand flies at some point after treatment (2 dogs or 16.6% in Group A, 2 or 22.2% in Group B and
none in Group C). Only 7.7% of the entire study population could infect sand flies as from the second month post-
treatment onset.
Conclusion: The three treatment regimens tested significantly reduced the infectivity of dogs towards sand flies,
thus diminishing the epidemiological risks of treated dogs both for human beings and other healthy dogs. Despite
its low cure rate, the use of allopurinol after a course of leishmanicide treatment is proposed to keep dogs non-
infectious during the disease transmission season (4-6 months in southern Europe).
Background
Leishmaniosis caused by the protozoan Leishmania
infantum is a severe parasitic disease that is spread to
humans and animals by blood-sucking phlebotomine
sand flies. Leishmaniosis is endemic in the Mediterra-
nean basin. In Spain, the proven vectors for L. infantum
are Phlebotomus perniciosus and Phlebotomus ariasi
[1-3], the former being the main vector. Dogs are the
main domestic reservoir of the parasite and play a role
in human infection [4]. Notwithstanding, the epidemio-
logical role of the cat is today a subject of intense
research [5-10] and it has been confirmed through
direct xenodiagnosis that cats presenting clinical signs
of the disease are able to infect sand flies [11,12].
Canine leishmaniosis (CanL) is today one of the most
important imported canine diseases in Central Europe
[13]. Estimates of CanL seroprevalence reported for
Spain range from 3.7% for the Orense province in the
northwest corner of the country [14] to 34.6% for the
province of Málaga on the south coast [15]. In the
Madrid region, a significant increase in the seropreva-
lence of CanL (from 5.25% to 8.1%) and the densities of
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any medium, provided the original work is properly cited.b o t hi t sv e c t o r s( P. perniciosus and P. ariasi) have been
detected with respect to surveys conducted 15 and
17 years ago, respectively [16,17].
Clinical CanL shows a wide spectrum of clinical signs
because of the many pathogenic mechanisms involved
and the particular host immune response [18]. However,
in areas where the disease is endemic a large number of
infected dogs are asymptomatic (clinically healthy
infected dogs) [19] but remain infective to sand flies
[20,21]. An early diagnosis and effective treatment of
sick dogs could help prevent the disease spreading to
other dogs and/or humans.
In Europe, treatment generally consists of various
dosage regimens of leishmanicides (mainly pentavalent
antimonials or secondly, miltefosine) combined with
allopurinol (a leishmanistatic drug) [22-25]. Allopurinol
has proved highly effective at maintaining successfully
treated dogs in long term clinical remission. However,
these treatments are of questionable efficacy because
most treated dogs are clinically cured but remain
infective [20,26,27].
To determine the epidemiologic risks of CanL, the
role of the dog as a natural reservoir for L. infantum
and the capacity of the sand fly vector to transmit
infected forms of Leishmania need to be addressed. To
date, few studies have assessed the infection capacity of
treated L. infantum-parasitized dogs through xenodiag-
nosis [20,26,28,29]. This is because the method is com-
plex and colonies of phlebotomine vectors need to be
kept in laboratory conditions throughout a complete life
cycle of the insect [30,31].
This study was designed to assess through xenodiag-
nosis the infection capacity of dogs naturally infected
with L. infantum before and after receiving three differ-
ent treatment regimes, and to examine the clinical and
parasite course.
Methods
Animals
This survey was carried out at the Veterinary Teaching
Hospital of the Universidad Complutense de Madrid
(Madrid, Spain). The dogs selected were 32 dogs
infected with L. infantum that consecutively attended
the clinic. The owners of the dogs enrolled were pre-
viously informed about the study protocol.
Dogs were included in the study if they met all the
following criteria:
- at least two clinical signs consistent with CanL:
asthenia and/or loss of weight, skin lesions, lym-
phoadenomegaly and/or splenomegaly, epistaxis -
sporadic or persistent (unilateral or bilateral), ocular
lesions, alterations in digestive function and/or
joints.
- a positive indirect immunofluorescence antibody
test (IFAT) for leishmaniosis-specific antibodies
(cut-off 1:100).
- parasite observed in cultures of bone marrow aspi-
rates grown in Novy-Nicolle-McNeal medium and/
or promastigotes detected by direct xenodiagnosis.
Dogs with CanL were excluded if they fulfilled one of
the criteria:
- concomitant infectious or vector-borne disease.
- pregnant or lactating female.
- severe renal, hepatic or cardiac failure.
- prior treatment with leishmanicides or
corticosteroids.
Sample collection
Dogs were examined four times throughout the study:
before treatment (Day 0) and at 60, 120, and 180 days
post-treatment (dpt) onset. On Day 0, dogs underwent
an electrocardiogram to rule out heart disease. At each
time point, blood, urine and bone marrow samples were
collected and animals were scored for 13 clinical signs
assessed in a physical examination using a categorized
scoring system from 0 to 2 (Table 1).
Table 1 Scoring system used for the different clinical
variables assessed before and after beginning treatment
CLINICAL SIGNS 0 1 2
Weight normal reduced cachexia
Appetite normal reduced anorexia
Behavior normal apathy postration
Lymphoadenomegaly absent localized generalized
Epistaxis absent moderate severe
Cutaneous keratoseborrhea absent moderate generalized
Ulcers absent simple multiple
Onicogriphosis absent moderate severe
Ocular lesions absent moderate severe
Digestive disorders absent mild severe
Arthropathy absent simple multiple
Amyotrophy absent moderate severe
Polyuria/Polydipsia absent moderate severe
CLINICAL-PATHOLOGICAL
ABNORMALITIES
01 2
Proteins normal elevated reduced
A/G ratio normal reduced -
Urea normal elevated -
Creatinine normal elevated -
ALT normal elevated -
Complete blood count 0 = normal, 1 = anemia,
2 = leukocytosis, 5 = anemia +
leukopenia, 7 = anemia +
leukocytosis
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blood and urine data (urea, creatinine, ALT and protein
electrophoresis). Additionally, the dogs were scored for 6
clinical-pathological abnormalities (Table 1). The IFAT for
anti-Leishmania-specific immunoglobulin G (IgG) antibo-
dies was performed as described previously [32] using the
cut-off 1:100. Serum samples were also tested for the pre-
sence of anti-Ehrlichia canis IgG antibodies [33].
For each dog, we conducted selective culture of bone
narrow aspirates on Novy-McNeal-Nicolle medium
(NNN) and prepared three Giemsa-bone marrow smears
to detect the presence of L. infantum amastigotes.
Treatment protocol
Dogs were assigned to one of the three treatment
groups:
Group A: Meglumine antimoniate and allopurinol
- 35 mg/kg of meglumine antimoniate given sub-
cutaneously twice daily for 28 days.
- 10 mg/kg of allopurinol given orally twice daily for
six months.
Group B: Meglumine antimoniate
- 35 mg/kg of meglumine antimoniate given sub-
cutaneously twice daily for 28 days.
Group C: Allopurinol
- 10 mg/kg of allopurinol given orally twice daily for
six months.
Xenodiagnosis
The infectivity of dogs was assessed through direct
xenodiagnosis. The local colony of P. perniciosus used in
this study had been laboratory-reared at the Instituto de
Salud Carlos III, Madrid [30]. The colony was kept in a
chamber under controlled conditions of temperature
(27-28°C), relative humidity (95-100%) and light cycle
(17 hours light/7 hours dark).
Dogs were sedated by the intravenous injection of 0.5
mg/kg of medetomidine and their heads introduced into
individual cube-shaped nets (50 cm wide × 50 cm high
× 50 cm deep). Before treatment (Day 0) and 60, 120,
and 180 dpt onset, dogs were exposed for one hour to
100 unfed, 7-day-old female sand flies released inside
the nets. After one hour of exposure, the sand flies were
carefully collected using a mouth aspirator. Fed flies col-
lected from each dog were separated into individual nets
(15 × 15 × 15 cm). Next the dogs were removed from
their cages and intravenously administered 0.25 mg/kg
of atipamezole.
F e ds a n df l i e sw e r ek e p ti n s i d et h ec h a m b e r sf o r
5-7 days. Engorged females were dissected and the sand
fly midgut was examined under a light microscope to
detect L. infantum promastigotes.
Outcome variables
The leismanicidal efficacy of treatment was assessed by
examining bone marrow cultures over time. The infection
capacity of the dogs was determined through xenodiagno-
sis at the different time points. The clinical course of the
dogs was examined in each of the treatment groups by
determining two indicators: percentage reduction in clini-
cal score and percentage reduction in clinical-pathological
abnormality score. Both of these indicators were calculated
as: score Day 0 - score dpt/score Day 0).
Statistical analysis
Quantitative data for the clinical signs and clinical-patholo-
gical abnormalities monitored are provided as medians and
their corresponding interquartile ranges. Categorical
variables are given as percentages. Baseline variables were
compared among the groups using the Chi-squared test, or
Fisher’s exact test for categorical variables. The Kruskal-
Wallis test was used to compare quantitative variables. To
detect differences among groups and examine changes pro-
duced over time in the four outcome variables (leishmanici-
dal efficacy, infection capacity, percentage reduction in
clinical signs and percentage reduction in clinical-patholo-
gical abnormalities), we constructed 4 longitudinal marginal
models, one per outcome measure, using a generalized esti-
mating equation (GEE) procedure. For leishmanicidal effi-
cacy and infectivity to sand flies, marginal longitudinal
models for binary data were used. Clinical sign and clinical-
pathological abnormality percentage reductions were nor-
malized by transforming these data into arc sen
√
p.
All analyses were performed using Stata v. 10.1 soft-
ware (StataCorp LP, College Station, Texas, USA).
Results
Table 2 shows the baseline characteristics of the dogs in
the three treatment groups revealing no significant dif-
ferences among them (p > 0.1). All dogs showed clini-
cal-pathological abnormalities associated with the
disease. Of the 32 dogs initially recruited, 6 were with-
drawn from the study (2 from Group B and 4 from
Group C) for several reasons: clinical failure, pregnancy,
diabetes, intestinal obstruction, surgery or death. This
left a final study population of 26 dogs; 9 females and
17 males aged from 9 months to 9 years. Of these dogs,
16 were pure breed and 10 were mongrels.
Leishmanicidal efficacy
The results of the bone marrow cultures shown in Table 3
indicate a drop in the number of dogs positive for the
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groups. In Group A, the 8 dogs testing positive (67%) on
Day 0 had dropped to 3 dogs (25%) at 180 dpt onset. In
Group B, 9 dogs (100%) initially testing positive, dropping
to 1 dog (11%) after 180 days of treatment and in Group
C, the corresponding numbers were 4 (80%) and 1 (20%).
Our marginal longitudinal models revealed the significant
(p < 0.001) and similar (p > 0.1) nature of these reductions
from Day 60 across all three groups.
Infectivity to sand flies
Our xenodiagnosis experiments also revealed a consider-
able drop in the infectivity of the differently treated dogs
in all 3 groups (Table 3). Thus, in Group A, numbers of
infectious dogs over the study period fell from 8 (67%)
to no dogs. In Group B, numbers dropped from 6 (67%)
to 1 (11%), and in Group C, from 3 (60%) to zero. Mar-
ginal models once again indicated that these reductions
were both similar (p > 0.1) and significant (p < 0.001)
after 60 days post-treatment onset in all three groups.
Clinical efficacy
Before the onset of treatment, the 26 dogs showed a
median clinical score of 6 points. When the clinical
course of disease was assessed in terms of the mean
reduction in this score, significant differences were
detected over time (p < 0.05) with respect to Day 0.
When these reductions were compared among the
groups, Group A treatment emerged as significantly
more effective (p < 0.05) compared to the other two
treatment regimens (Figure 1).
Improved clinical-pathological abnormalities expressed
as mean percentage reductions in scores observed indi-
cated no significant differences (p < 0.05), improvements
being observed only with respect to baseline (Day 0)
scores. After treatment, significant differences were
Table 2 Baseline characteristics of the dogs included in the three different treatment groups
Group A Group B Group C
N1 2 1 1 9
AGE (years), median (p25-p75) 4 (3-5) 3 (2-8) 5 (4-7)
PROT (g/dl), median (p25-p75) 8 (7.6-10.1) 7.2 (6.8-9.8) 8.5 (7.4-8.8)
A/G (g/dl), median (p25-p75) 0.44 (0.38-0.49) 0.46 (0.36-0.57) 0.43 (0.42-0.66)
UREA (mg/dl), median (p25-p75) 36 (29-45) 34 (26-48) 36 (30-46)
CREAT (mg/dl), median (p25-p75) 0.78 (0.72-0.87) 0.69 (0.59-0.9) 0.86 (0.66-0.98)
ALT (U/l), median (p25-p75) 67 (45-100) 57 (46-146) 89 (54-98)
CLIN SCORE, median (p25-p75) 6 (4-7) 6 (5-9) 6 (5-6)
ANALYTICAL SCORE, median (p25-p75) 5 (3-10) 3 (3-4) 3 (2-4)
IFAT, median (p25-p75) 800 (400-1600) 800 (800-1600) 400 (200-400)
CBC n, (%)
* 9 (75) 4 (36) 5 (56)
*Percentage of dogs showing abnormal CBC (anemia, leukocytosis or leukopenia).
CBC: complete blood count; ALT: Alanine trnsaminase; A/G: Albumin/Globulin ratio.
Table 3 Bone-marrow culture and xenodiagnosis results
recorded before and after starting treatment in each dog
Dog Bone narrow culture Xenodiagnosis
D0 D60 D120 D 180 D0 D60 D120 D 180
A1 + + + + + - + -
A2 + - - + + - - -
A3 - - - - + - - -
A4 + - - - - - - -
A5 + - - - - - - -
A6 - - - - + - - -
A7 + - - - + - - -
A8 - - - - + - - -
A9 + - - - - - - -
A10 - - - - + - - -
A11 + - - - + + - -
A12 + - - + - - - -
B1 + - - - + - - -
B2 + - - - + + - -
B3 + - - - + - - -
B 4 + - -+ - - -+
B5 + - - - + - - -
B6 + - - - - - - -
B9 + - - - - - - -
B10 + - - - + - - -
B11 + - - - + - - -
C1 - - - - + - - -
C3 + + + + + - - -
C5 + + - - + - - -
C7 + - + - - - - -
C9 + - + - - - - -
+ indicates positive culture result or infectious dog.
D0, D60, D120 and D180 indicate the time points before treatment and after
60, 120 or 180 days of treatment respectively.
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treatment emerged as more effective (p < 0.05) than the
remaining treatments (Figure 2).
Discussion
To date, the use of xenodiagnosis to assess the efficacy
of treatment, measured as the infection capacity of trea-
ted dogs naturally infected with L. infantum,h a so n l y
been reported in four studies including 4, 2, 36 and 10
dogs respectively [20,26,28,29]. The present survey along
with the study by Ribero et al. (2008) [28] was con-
ducted on a sufficiently large sample size for valid con-
clusions to be drawn.
A sm a yb eo b s e r v e di nF i g u r e s1a n d2 ,t h em o s t
effective of our treatment regimens in terms of clinical
improvement was the combined use of antimonials and
allopurinol (Group A). Notwithstanding, we and other
authors have noted that in some measure all treatments
are able to improve the clinical condition of dogs
[20,26,28,29].
By examining the capacity of the dogs to infect sand
flies, we observed a considerable reduction in the infec-
tivity of the dogs in response to the three treatments
tested. Only 7.7% of the entire study population was
able to infect sand flies after the second month of treat-
ment. This finding suggests that similarly treated dogs
will not play a major role in promoting or maintaining
new foci of disease spread.
The liposome formulation of meglumine antimoniate
has been described to significantly diminish the capacity
of dogs to infect Lutzomyia longipalpis five months after
the end of treatment [28]. In prior work, we observed a
lack of infectivity towards sand flies of 6 dogs treated
with meglumine antimoniate and allopurinol for at least
4 months post-treatment onset [20]. In early studies,
treatment with meglumine antimoniate was found to
reduce the percentage of sand flies becoming infected
after feeding on treated dogs [26,29].
The bone marrow culture results indicate that
regardless of a favorable clinical outcome of treatment,
30.8% of the dogs still showed the presence of the
parasite in some of the check ups. These animals can
be described as not parasitologically cured, or carriers
of the parasite.
In the survey conducted in Brazil, bone marrow para-
site burden was significantly reduced 4 days after the
end of treatment with meglumine antimoniate [28]. In
addition, it was observed that five of six dogs treated
with meglumine antimoniate plus allopurinol still har-
bored parasites in the spleen 10 months after treatment
[20].
It should be highlighted that in the treatment Group
C of the present study, 80% of the dogs remained
infected at the end of the study. This would appear to
point to the ineffective nature of treatments based solely
on allopurinol since, despite showing clinical improve-
ment, these still infected animals could experience dis-
ease recrudescence. However, xenodiagnosis of the dogs
in Group C indicated no evidence of the spread of the
parasite to the phlebotomine sand flies. This finding has
significant epidemiological implications in that although
allopurinol may not be an effective shock treatment, it
could perhaps be used in longer treatment maintenance
courses (6-12 months). Notwithstanding, this should be
done under supervision given the known long-term
adverse effects of this agent (nephrolithiasis due to
xanthine) [34,35].
The bone marrow culture and xenodiagnostic findings
indicate that by Day 180 after the onset of treatment
(A, B or C), 81% of the dogs had been “cured” or the
parasite had been eliminated, although in some dogs
(11.1 to 25%) it persisted for a variable length of time.
Figure 1 Percentage reductions in clinical signs produced in
response to treatment.
Figure 2 Percentage reductions in clinicopathological
abnormalities produced in response to treatment.
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sick dogs since these represent a serious epidemiological
risk. Despite not being a simple method, the xenodiag-
nostic approach used here emerged as a useful tool to
assess the infection capacity of dogs treated with new
drugs and/or new treatment regimens. A reduction in
infectivity to sand flies in response to treatment is a key
factor to consider in control programs designed to era-
dicate active foci of canine leishmaniosis. In endemic
areas there is a plenty of evidence indicating the effec-
tiveness of repellents against sand flies in reducing the
spread of Leishmania infection.
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